|
|
|
|
|
|
|
|
The Latest Research, Commentary, and News from Health Affairs
Tuesday, November 19, 2019
|
|
|
|
|
|
|
|
|
TODAY ON THE BLOG
PAYMENT
Private Equity And Powerful Physician Groups Raise Another Distraction
By Hunter Kellett, Alexandra Spratt, and Mark E. Miller
Congress can help close a damaging loophole in the health care system by bringing everyone to the negotiating table. Read More >>
PHARMACEUTICALS & MEDICAL TECHNOLOGY
Toward Continuous Evidence-Based Treatment For Opioid Use Disorder: Lessons from North Carolina
By Aaron McKethan, Hilary Campbell, Andrew Olson, Susan Kansagra, Elyse Powell, and Emma Sandoe
We aim to draw attention, both within and beyond North Carolina, to learning that can increase the rate at which people with OUD receive appropriate, ongoing, evidence-based treatment. These findings are relevant for North Carolina and, we believe, instructive for state and federal policy making as we explore ways to make further progress related to the opioid epidemic. Read More >>
|
|
|
PHARMACEUTICALS & MEDICAL TECHNOLOGY
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage
By James D. Chambers, Ari D. Panzer, Elle F. Pope, Jennifer S. Graff, and Peter J. Neumann
Researchers have reported wide variation in how commercial health insurance plans cover specialty drugs, which suggests that a patient’s health plan can determine their access to these treatments. James Chambers and coauthors used information from the Tufts Medical Center Specialty Drug Evidence and Coverage Database to examine the evidence that plans reported reviewing in
specialty drug coverage policies. Read More >>
Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage
By Pinar Karaca-Mandic, Jessica Chang, Ronald Go, Stephen Schondelmeyer, Daniel Weisdorf, and Molly Moore Jeffery
Pinar Karaca-Mandic and coauthors report on the uptake and costs of the first biosimilar in the US market, filgrastim-sndz (Zarxio). Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among the commercially insured and 42 percent among Medicare Advantage beneficiaries. Read More >>
|
|
|
|
|
|
|
HEALTH AFFAIRS EVENTS–PAST EVENT: MILITARY HEALTH SYSTEMS
The August 2019 issue of Health Affairs examines the Military Health System and the pressures and opportunities that are similar to those in the civilian sector. Get caught up with the Military
Health Systems event: slides (click on Download Event), video, and podcast.
Access the August PRINT or ONLINE issue.
Get event-specific emails delivered directly to your inbox.
|
|
|
|
|
A CLOSER LOOK—Youth Mental Health
Most American parents say that they might have trouble distinguishing between a teen's typical mood swings and possible signs of depression, a new survey published Monday finds. This Health Affairs Blog post from 2015 argues that health care systems and schools must place high priority on early screening and prevention of
mental health problems in youth.
|
|
|
|
|
|
|
|
|
|
|
|
|
About Health Affairs
Health Affairs is the leading peer-reviewed journal at the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday
Update.
Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.
Copyright © Project HOPE: The People-to-People Health Foundation, Inc.
Health Affairs, 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814, United States
Privacy Policy
|
|
|
|
|
